Fondaparinux Sodium: Recent Advances in the Management of Thrombosis
Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary embolism, and superficial vein thrombosis, in acutely ill (including those affected by COVID-19 or cancer...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-01-01
|
Series: | Journal of Cardiovascular Pharmacology and Therapeutics |
Online Access: | https://doi.org/10.1177/10742484221145010 |